Skip to main content

Acne Foam Recalled Over Superpotency

April 13, 2018

More than 3000 cans of Fabior (tazarotene) Foam, 0.1% (NDC 51862-295-10), are being recalled by Mayne Pharma due to superpotency concerns, according to the April 11, 2018, US Food and Drug Administration (FDA) Enforcement Report.

The recall affects 100-gram cans from lot MBEB (Exp. 1/31/19). The cans were distributed across the United States.

Mayne Pharma voluntarily initiated the recall March 21, 2018. The FDA designated it a Class III recall March 30, 2018. The classification signals use of the foam is not likely to cause adverse health consequences.

Fabior Foam is a topical prescription retinoid approved for the treatment of acne.

Jolynn Tumolo

For more Pharmacy Learning Network articles, visit the homepage

To learn about Pharmacy Learning Network Live meetings, click here

Back to Top